Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.bibcol.com | |
Market Cap | 111.62 Cr. | |
Enterprise Value(EV) | 183.62 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -2.03 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 32.54 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | -3.35 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | -7.71 | Calculated using Price: 25.85 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 4.32 Cr. | 43,180,000 Shares |
FaceValue | 10 | |
Company Profile | ||
The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh. |
1 Day |
|
-3.18% |
1 Week |
|
-8.01% |
1 Month |
|
-35.21% |
3 Month |
|
+5.51% |
6 Month |
|
-1.34% |
1 Year |
|
-46.37% |
2 Year |
|
-65.49% |
5 Year |
|
+1.97% |
10 Year |
|
+87.59% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.68 | 3.81 | -16.25 | 16.94 | -10.76 | -17.00 | -39.93 | -158.64 | ||
Return on Capital Employed (%) | 42.29 | 9.07 | -8.52 | 31.11 | -17.52 | -10.70 | -21.87 | -73.05 | -8.08 | |
Return on Assets (%) | 7.28 | 1.81 | -8.50 | 10.80 | -8.51 | -7.22 | -8.97 | -18.41 | -6.35 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 40 | 41 | 35 | 42 | 38 | 31 | 20 | 34 | 105 | 97 | |
Non Curr. Liab. | 3 | 4 | 1 | -1 | -5 | -4 | -8 | -14 | -15 | -17 | |
Curr. Liab. | 48 | 35 | 30 | 14 | 13 | 88 | 101 | 64 | 101 | 107 | |
Minority Int. | |||||||||||
Equity & Liab. | 91 | 80 | 66 | 55 | 45 | 115 | 113 | 84 | 192 | 187 | |
Non Curr. Assets | 7 | 7 | 6 | 8 | 7 | 16 | 20 | 50 | 126 | 129 | |
Curr. Assets | 84 | 74 | 60 | 47 | 38 | 99 | 93 | 34 | 65 | 58 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 91 | 80 | 66 | 55 | 45 | 115 | 113 | 84 | 192 | 187 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 79 | |
Other Income | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 1 | |
Total Income | 209 | 147 | 129 | 125 | 36 | 88 | 68 | 87 | 79 | 80 | |
Total Expenditure | -191 | -143 | -132 | -111 | -43 | -93 | -77 | -106 | -83 | -89 | |
PBIDT | 18 | 4 | -3 | 14 | -7 | -5 | -9 | -19 | -4 | -9 | |
Interest | -6 | -1 | -6 | -4 | -1 | -2 | -5 | -5 | -6 | -6 | |
Depreciation | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | -5 | -1 | 3 | -3 | 4 | 2 | 4 | 6 | 1 | -3 | |
Exceptional Items | |||||||||||
PAT | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -18 | |
Adjusted EPS | 1 | 0 | -1 | 2 | -1 | -1 | -2 | -4 | -2 | -4 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | |
Cash Fr. Inv. | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
Cash Fr. Finan. | 0 | -6 | -1 | -2 | -3 | -3 | 31 | -34 | -12 | 45 | |
Net Change | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | |
Cash & Cash Eqvt | 41 | 23 | 30 | 20 | 0 | 1 | 0 | 1 | 1 | 5 |
Tue, 27 Dec 2022
Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd The Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd on December 27 2022 with reference to Movement in Price. The reply is awaited. |
||||||||||||||
Mon, 17 Oct 2022
Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended September 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015 In pursuance of the SEBI LODR please find attached the Un-audited Quarterly Financial Results for the quarter ended September 2022 and Limited Review Report thereon as per the Compliance of LODR 2015 |
||||||||||||||
Tue, 11 Oct 2022
Statement Of Investor Complaints For The Quarter Ended September 2022
|
Tue, 31 Jan 2023 |
|
|
|
|
|